ED
BCRX icon

Exane Derivatives’s BioCryst Pharmaceuticals BCRX Stock Holding History

Exane Derivatives’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$338 Sell
32
-7,495
-100% -$77.3K ﹤0.01% 618
2022
Q1 		$122K Sell
7,527
-3,819
-34% -$61.3K 0.03% 438
2021
Q4 		$157K Buy
11,346
+4,727
+71% +$62.6K 0.04% 381
2021
Q3 		$95.1K Buy
+6,619
New +$104K 0.02% 530

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Exane Derivatives's BCRX Position: Q2 2022 in Review

Exane Derivatives reduced its BioCryst Pharmaceuticals (BCRX) stake by 100% in Q2 2022, selling an estimated $77.3K and leaving 32 shares worth $338. The position accounts for ﹤0.01% of the portfolio, ranked #618.

Exane Derivatives first reported a position in BCRX in Q3 2021 and has held it in 4 quarters since. The position peaked at $157K in Q4 2021. 220 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Exane Derivatives held 32 shares of BioCryst Pharmaceuticals worth $338 as of Q2 2022.
  • Exane Derivatives sold 7,495 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $77.3K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #618 holding.
  • Exane Derivatives first reported a position in BioCryst Pharmaceuticals in Q3 2021 and has held it in 4 quarters since.
  • Exane Derivatives's BioCryst Pharmaceuticals position peaked at $157K in Q4 2021.
  • 220 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.